Effects of Neurofeedback Training and tRNS on Attentional Deficits in Patients With Acquired Brain Injury
NCT: NCT07817316 · RECRUITING
Brief Summary
The goal of this study is to investigate new neuromodulation therapies for attention deficits following acquired brain injury. Brain damage can affect various domains, including motor and cognitive functions. However, cognitive deficits have many consequences on the functionality and independence of patients, and attention is an essential requirement for most of daily activities. After brain damage, cognitive rehabilitation is generally the first treatment option for attention deficits. Some studies have shown that cognitive rehabilitation is sometimes not very effective.For this reason, new therapies such as neuromodulation techniques are being investigated. Neurofeedback is a non-invasive neuromodulation therapy involving a type of computer-based training and learning, and some studies have shown that it is a promising tool to treat cognitive deficits in patients with brain injuries. Transcranial electrical stimulation (tES) is also used to modulate spontaneous brain activity. In the present study, the investigators will evaluate the effects of tES combined with neurofeedback as a therapy for attentional deficits after brain injury.
Frequently Asked Questions
What is Effects of Neurofeedback Training and tRNS on Attentional Deficits in Patients With Acquired Brain Injury?
Effects of Neurofeedback Training and tRNS on Attentional Deficits in Patients With Acquired Brain Injury is a clinical trial registered under NCT07817316. Current status: RECRUITING.
What is the status of NCT07817316?
The current status of NCT07817316 (Effects of Neurofeedback Training and tRNS on Attentional Deficits in Patients With Acquired Brain Injury) is: RECRUITING.
When did Effects of Neurofeedback Training and tRNS on Attentional Deficits in Patients With Acquired Brain Injury start?
Effects of Neurofeedback Training and tRNS on Attentional Deficits in Patients With Acquired Brain Injury started on 2026-06-26.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.